Research Antibodies: Solutions for Today and Tomorrow

项目摘要/摘要 抗体是世界各地不可或缺的生物试剂，但也是 目前临床前研究中的重复性危机。各种各样的问题可能会危及 基于抗体的生物医学实验，而无法复制已发表的数据通常 被追踪到没有得到适当验证的抗体。本次NIH/NIGMS研究会议 (R13)助学金计划将帮助资助由全球 生物标准研究所和抗体学会，2016年9月25日至27日，在 Asilomar会议在加利福尼亚州的太平洋格罗夫举行。研讨会将是一个中心部分 这是一个为期一年的进程，将吸引主要专家和利益攸关方代表 研究并提出可在整个生命科学领域采用的潜在解决方案。这个 会议将集中讨论该领域的关键问题，包括定性的标准化， 性能，抗体的验证，以及重组， 测序抗体作为提高质量的长期潜在途径， 基于抗体的临床前研究的可重复性和可转译性。大约80 计划参加讲习班，包括7名指导委员会成员和38名小组成员 涉及8个小组、30名额外的专家与会者以及5名工作人员和承包商。工作坊 以及相关产品将帮助更广泛的生命科学研究界达成共识 围绕短期和长期解决方案，以解决普遍缺乏具有良好特征的 以及生物医学研究中的有效抗体。

Project Summary/Abstract Antibodies are indispensable biological reagents around the world, yet are a major contributor to the current reproducibility crisis in preclinical research. A variety of issues can jeopardize antibody-based biomedical experiments, while the inability to replicate published data can often be traced to antibodies that were not properly validated. This NIH/NIGMS Research Conference (R13) Grant proposal will help fund a workshop co-sponsored and co-hosted by the Global Biological Standards Institute and The Antibody Society on September 25–27, 2016, at the Asilomar Conference Grounds in Pacific Grove, California. The workshop will be a central part of a year-long process that will engage key experts and stakeholder group representatives to examine and propose potential solutions that can be adopted across the life sciences. The meeting will focus on critical issues in the field, including standardization of characterization, performance, and validation of antibodies, as well as the introduction of recombinant, sequenced antibodies as a long-term potential path forward to improving the quality, reproducibility, and translation of antibody-based preclinical research. Approximately 80 workshop participants are planned, including 7 Steering Committee members, 38 panelists across 8 panels, 30 additional expert participants, and 5 staff and contractors. The workshop and related products will help the broader life science research community reach consensus around both short- and long-term solutions to address the pervasive lack of well characterized and validated antibodies in biomedical research.